Israel Englander Neurocrine Biosciences Inc Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Millennium Management LLC holds 455,220 shares of NBIX stock, worth $61.6 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

455,220

Previous 688,956 33.93%

Holding current value

$61.6 Million

Previous $90.8 Million 30.84%

% of portfolio

0.03%

Previous 0.04%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $30.5 Million - $33.6 Million	-233,736 Reduced 33.93%	455,220 $62.8 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $17.1 Million - $21.4 Million	-161,302 Reduced 18.97%	688,956 $90.8 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $25.2 Million - $29.6 Million	281,983 Added 49.62%	850,258 $80.2 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $25.6 Million - $33.5 Million	-272,065 Reduced 32.38%	568,275 $57.5 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $28.5 Million - $34 Million	267,284 Added 46.64%	840,340 $100 Million

Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $19.4 Million - $22.7 Million	210,383 Added 58.01%	573,056 $60.9 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $10.4 Million - $13.8 Million	-137,454 Reduced 27.48%	362,673 $35.4 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $4.41 Million - $5.77 Million	-60,870 Reduced 10.85%	500,127 $46.9 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $5.56 Million - $7.41 Million	69,753 Added 14.2%	560,997 $47.8 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $31.9 Million - $36.6 Million	369,733 Added 304.28%	491,244 $47.1 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $9.27 Million - $10.6 Million	-103,645 Reduced 46.03%	121,511 $11.8 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $15.9 Million - $19.8 Million	182,520 Added 428.09%	225,156 $21.6 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $1.59 Million - $2.23 Million	-16,514 Reduced 27.92%	42,636 $4.1 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $4.91 Million - $7.52 Million	-57,650 Reduced 49.36%	59,150 $7.22 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $20.2 Million - $30.6 Million	-269,258 Reduced 69.75%	116,800 $10.1 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $9.46 Million - $12.9 Million	109,006 Added 39.34%	386,058 $41.5 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $6.15 Million - $7.44 Million	73,342 Added 36.0%	277,052 $25 Million
Q2 2019 Aug 15, 2019	SELL	$72.24 - $91.27 $36.9 Million - $46.7 Million	-511,295 Reduced 71.51%	203,710 $17.2 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $11.2 Million - $14.2 Million	155,057 Added 27.69%	715,005 $31.3 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $37.4 Million - $49.4 Million	539,208 Added 2599.85%	559,948 $49.3 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $23.1 Million - $42 Million	-337,795 Reduced 94.22%	20,740 $1.48 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $32.8 Million - $41.7 Million	331,346 Added 1218.68%	358,535 $44.1 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $7.58 Million - $10.7 Million	-100,726 Reduced 78.74%	27,189 $2.67 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $30.9 Million - $37.6 Million	-406,651 Reduced 76.07%	127,915 $10.6 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $24.4 Million - $32.4 Million	417,661 Added 357.27%	534,566 $41.5 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $5.61 Million - $7.16 Million	116,905	116,905 $7.16 Million

Others Institutions Holding NBIX

# of Institutions

631

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account